Case Report: Vesicorectal Fistula Caused by Intestinal Tuberculosis Complicated with Systemic Lupus Erythematosus
Pengjia Wu,Jiashun Zeng,Lei Yang
DOI: https://doi.org/10.2147/IDR.S383893
2022-10-28
Infection and Drug Resistance
Abstract:Pengjia Wu, Jiashun Zeng, Lei Yang Department of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550000, People's Republic of China Correspondence: Jiashun Zeng, Email Patients with systemic lupus erythematosus (SLE) are prone to various infections due to autoimmune defects and long-term use of immunosuppressive agents. Mycobacterium tuberculosis (TBC) infection is a common infection in patients with SLE, especially in developing countries such as China. SLE and TBC may overlap and confuse a clinical picture, bringing great difficulties for the diagnosis and treatment. This article reports a case of vesicorectal fistula caused by intestinal TBC complicated with SLE, where the manifestation was recurrent diarrhea, initially treated as lupus-associated intestinal vasculitis without notable response. This case suggests that we should pay attention to close monitoring of tuberculosis-related indicators during the follow-up period of SLE patients, especially in endemic areas, and early diagnosis and treatment of TBC can reduce tuberculosis-related complications and significantly improve the quality of life of patients. Keywords: systemic lupus erythematosus, vesicorectal fistula, intestinal tuberculosis, infect, diarrhea The prevalence of TBC infection in patients with SLE is higher than that in the general population, especially in developing countries. According to the WHO, in 2019, about 10 million people were infected with TBC, in other words, on average, 130 per 100,000 people were suffering from TBC. 1 During the treatment of SLE with glucocorticoids and immunosuppressive agents, the incidence of mycobacterium TBC infection increases significantly, mainly, in severe TBC and extrapulmonary TBC. 2–5 A meta-analysis of data from 35 studies, including 46,327 SLE patients in 13 countries, showed that the prevalence of TBC in SLE patients was 3.59%. 6 The clinical manifestations of TBC are diverse and non-specific, so the diagnosis is very difficult. In addition, because the clinical picture of intestinal TBC and lupus intestinal vasculitis are extremely similar, both of them are often manifested as abdominal pain, diarrhea, nausea, vomiting, etc, which often leads to misdiagnosis or untimely diagnosis, therefore, there are very few relevant reports. Intestinal TBC can lead to malabsorption syndrome, obstruction, perforation, and fistula. When patients have chronic perforation, the abscess can be formed in the abdominal cavity, and then rupture of the abscess can cause an intestinal fistula, resulting in a connection between bladder and intestine. This can significantly threaten the patient's life without a clear diagnosis and timely treatment. Here we report a rare case of vesicorectal fistula caused by intestinal TBC complicated with SLE, and to our knowledge, no such case has been reported. A 24-year-old female patient experienced rash and oral ulcers with arthralgia at the age of 19 years, when antinuclear antibodies and double-stranded DNA antibodies were positive. The patient was diagnosed with SLE based on her clinical manifestations and relevant immune test results. She was initially treated with prednisone 50 mg/day and hydroxychloroquine orally. She returned regularly with reasonable disease control, followed by a gradual reduction to prednisone 10 mg for long-term maintenance therapy. In August 2018, the patient began to experience repeated diarrhea with abdominal pain and occasional fever, with a body temperature up to 40°C, accompanied by nausea and anorexia. The stools varied from several to ten times a day and were yellow watery stools. No treatment was given. On October 17, 2018, the patient was admitted to the hospital. Blood routine: blood cell analysis (five-part differential): white blood cell count (WBC) 8.31G/L, neutrophil granulocyte% (NEUT%) 85%, red blood cell (RBC) 2.99T/L, hemoglobin (Hb) 74.00 g/L, hematocrit (HCT) 24.2%, platelet count (PLT) 295.00G/L. Urinalysis: RBC 1321.00 cells/ul, WBC 1636.00 cells/ul, urine protein + stool routine + occult blood test (OB): positive fecal occult blood. The stool smear revealed fungal spores and hyphae. High-sensitivity C-reactive protein 103.29 mg/L. The erythrocyte sedimentation rate was 94 mm/h. Coombs' test was positive. ANA antibody spectrum (containing anti-dsDNA) antinuclear antibody 1:1000 positive, anti-double-stranded DNA antibody negative, anti-Smith antibody weakly positive, anti-ribosomal P protein antibody strongly positive. Complement3 0.61 g/l, Complement4 0.14 g/l. T-cells enzyme linked immunospot (T-SPOT) was positive. Chest CT: interstitial change in both sides. For the patient. Considering the initial treatment by a variety of antibiotics was ineffective, and the fundamental disease is SLE, for which lupus associated intestinal vasculitis is a -Abstract Truncated-
pharmacology & pharmacy,infectious diseases